Ann: Veyonda Showing Potential to Prevent Cytokine Storm, page-27

Oh vrs. Even you must admit this is starting to look good. All 18 patients.... across multiple FAMILIES of cytokines (that is really exciting)... sub-optimal dosage... come on, join us, we all know you want to take the plunge, you might never get a better opportunity.

And the answers to all your questions are clearly articulated in the "NEXT STEPS" section.

Next steps
The biomarker data from the top Veyonda (1800 mg) dose cohort is expected within the next few
weeks. That will be followed by a review of the final clinical data on completion of treatment of
the final patient. Clinical status (WHO COVID-19 grade, co-morbidities) and other therapies will
need to be taken into account. After reviewing all data, the Company will consult with its medical
and business development advisors along with government bodies including drug regulators.